Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.57B | 2.58B | 2.56B | 2.61B | 2.67B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.57B | 2.58B | 2.56B | 2.61B | 2.67B |
| Cost of Revenue | 1.19B | 1.18B | 1.18B | 1.21B | 1.24B |
| Gross Profit | 1.38B | 1.40B | 1.38B | 1.39B | 1.43B |
| SG&A Expenses | 810.90M | 814.07M | 814.73M | 826.53M | 841.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.29B | 2.27B | 2.22B | 2.28B | 2.33B |
| Operating Income | 274.80M | 311.79M | 338.37M | 327.80M | 337.90M |
| Income Before Tax | -2.34B | -1.01B | -1.73B | -443.85M | -850.10M |
| Income Tax Expenses | -498.30M | -226.52M | -404.12M | -121.51M | -212.80M |
| Earnings from Continuing Operations | -1.84K | -778.67 | -1.33K | -322.35 | -637.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.84B | -778.67M | -1.33B | -322.35M | -637.30M |
| EBIT | 274.80M | 311.79M | 338.37M | 327.80M | 337.90M |
| EBITDA | 426.40M | 461.39M | 486.37M | 475.20M | 483.80M |
| EPS Basic | -65.00 | -27.28 | -47.00 | -10.33 | -21.46 |
| Normalized Basic EPS | 6.93 | 7.75 | 8.42 | 8.09 | 8.59 |
| EPS Diluted | -65.04 | -27.34 | -47.04 | -10.37 | -21.50 |
| Normalized Diluted EPS | 6.93 | 7.74 | 8.41 | 8.07 | 8.57 |
| Average Basic Shares Outstanding | 112.86M | 113.65M | 114.81M | 115.77M | 116.85M |
| Average Diluted Shares Outstanding | 112.91M | 113.73M | 114.97M | 115.93M | 117.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |